Growth Hormone Deficiency Market to Accelerate Substantially During the Forecast Period (2019-32) – Asserts DelveInsight | Key Companies- Ascendis Pharma, Pfizer, Opko health, Lumos Pharma, and Others

Growth Hormone Deficiency Market to Accelerate Substantially During the Forecast Period (2019-32) - Asserts DelveInsight | Key Companies- Ascendis Pharma, Pfizer, Opko health, Lumos Pharma, and Others
Delveinsight Business Research LLP
As per DelveInsight, the Growth Hormone Deficiency Therapeutics Market dynamics are expected to transform in the coming years owing to the launch of emerging therapies, the rise in the number of prevalent cases of Growth Hormone Deficiency in the 7MM, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment.

DelveInsight’s “Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Growth Hormone Deficiency Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Growth Hormone Deficiency market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Growth Hormone Deficiency Market

Growth Hormone Deficiency: An Overview

Growth hormone deficiency (GHD) is a condition where the pituitary gland cannot make enough growth hormone. It can be caused by damage to the pituitary gland or another gland called the hypothalamus. The injury can occur before birth (congenital), or during or after birth (acquired). A third category has no known or diagnosable cause (idiopathic).

A tumor may cause Growth Hormone Deficiency in the brain. These tumors are normally located at the site of the pituitary gland or the nearby hypothalamus region of the brain. In children and adults, serious head injuries, infections, and radiation treatments can also cause GHD, which is known as acquired GHD (AGHD). However, in rare cases, GHD can be part of a genetic syndrome such as Turner syndrome and Prader-Willi syndrome. Additionally, in many cases, the cause of Growth Hormone Deficiency (GHD) is not known or idiopathic.

Growth Hormone Deficiency Market Key Facts

  • As per the study by Bonfig et al. (2019) titled “Mini-Review/Commentary: Growth Hormone Treatment in Children with Type 1 Diabetes,” the prevalence of Growth Hormone Deficiency (GHD) ranges between 1/3500 and 1/8700 in Germany.

  • According to the Boston Children’s Hospital, about 1 in 4,000–10,000 children have Growth Hormone Deficiency.

  • According to the Growth Hormone Foundation estimates, more than 50,000 adults in the United States are growth hormone deficient, and 6,000 new cases are reported each year, including Growth Hormone Deficiency children who transition to GHD as an adult.

Growth Hormone Deficiency Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Growth Hormone Deficiency market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Growth Hormone Deficiency market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Growth Hormone Deficiency Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Growth Hormone Deficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Growth Hormone Deficiency market or expected to get launched during the study period. The analysis covers Growth Hormone Deficiency market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Growth Hormone Deficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Growth Hormone Deficiency Therapeutics Analysis

The dynamics of the Growth Hormone Deficiency (GHD) market are anticipated to change in the coming years owing to the rise in the number of healthcare spending across the world.

Some of the key companies in the Growth Hormone Deficiency (GHD) market include:

  • Ascendis Pharma

  • Pfizer

  • Opko health

  • Lumos Pharma

And others

Growth Hormone Deficiency (GHD) Therapies covered in the report includes:

  • TransCon hGH

  • Somatrogon

  • LUM-201

  • HyTropin

And many others

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Growth Hormone Deficiency Competitive Intelligence Analysis

4. Growth Hormone Deficiency Market Overview at a Glance

5. Growth Hormone Deficiency Disease Background and Overview

6. Growth Hormone Deficiency Patient Journey

7. Growth Hormone Deficiency Epidemiology and Patient Population

8. Growth Hormone Deficiency Treatment Algorithm, Current Treatment, and Medical Practices

9. Growth Hormone Deficiency Unmet Needs

10. Key Endpoints of Growth Hormone Deficiency Treatment

11. Growth Hormone Deficiency Marketed Products

12. Growth Hormone Deficiency Emerging Therapies

13. Growth Hormone Deficiency Seven Major Market Analysis

14. Attribute Analysis

15. Growth Hormone Deficiency Market Outlook (7 major markets)

16. Growth Hormone Deficiency Access and Reimbursement Overview

17. KOL Views on the Growth Hormone Deficiency Market.

18. Growth Hormone Deficiency Market Drivers

19. Growth Hormone Deficiency Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –


About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Chronic Focal Epilepsy Market
“Chronic Focal Epilepsy Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Chronic Focal Epilepsy Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States